CTRI/2010/091/000077已完成3 期
A prospective, active-controlled, randomized, double blind, comparative, parallel, 2-arm study to evaluate the efficacy and safety of Eperisone SR (150 mg)in patients suffering from acute muscle spasms.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- Pain intensity, tenderness, Joint mobility, Spasm relief, Need for rescue medication, Time needed for the patient to be symptom free
研究概览
简要总结
A prospective, active - controlled, randomized, double blind, comparative, parallel, 2-arm study to evaluate the efficacy and safety of Eperisone Sustained Release (150 mg) in patients suffering from acute muscle spasms. (200 PATIENTS ENROLLED)
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients of either sex in the age group between 18 to 70 years.
- •Patients painful muscle spasms and contractions associated with cervical and lumbar spondylosis, rheumatoid arthritis, osteoarthritis, blunt superficial trauma, low back pain.
- •Subjects who provide a written informed consent to abide by the study requirements.
排除标准
- •Patients with acute muscle spasms who need parenteral therapy / surgery / hospital admission for management.
- •Patients treated with any other oral / parenteral muscle relaxants, analgesics (NSAIDs & Opioids) medications within 1 week prior to the study.
- •Patients suffering from organic neurological disorders (Upper motor neuron disorders, cerebral palsy, pyramid tract injury, multiple sclerosis, cerebrovascular events, myelopathy, encephalomyelitis, etc), peripheral vascular diseases (arteriosclerosis obliterans, diabetic angiopathy, thrombangiitis obliterans, Raynaud's disease, diffuse scleroderma) as well as syndromes developing on the basis of impaired vascular innervation (acrocyanosis, dysbasia angioneurotica intermittent), Little's diseases and other encephalopathies accompanied by dystonia.
- •Patients suffering from myasthenia gravis or myopathies with muscle weakness as the prominent symptom.
- •Patients with known hypersensitivity to any of the ingredients of the test / comparator formulation.
- •Patients with severe cardiac, hepatic, gastrointestinal, renal, pulmonary and skin diseases.
- •Pregnant and lactating females.
- •Simultaneous participation in another clinical study.
结局指标
主要结局
Pain intensity, tenderness, Joint mobility, Spasm relief, Need for rescue medication, Time needed for the patient to be symptom free
时间窗: 0, 3 days, 7 days, 10 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
Phase 3 4
Study of the efficacy and safety of Epalrestat to Pregabalin in patients suffering from painful diabetic peripheral neuropathy.CTRI/2013/05/003646Investigator Initiated study240
已完成
3 期
A clinical study to evaluate the efficacy and safety of FDC of Tolperisone and Paracetamol in patients suffering from acute muscle spasmsCTRI/2010/091/000127Themis Medicare Limited200
已完成
3 期
Efficacy and safety ofR-TPR-024 / Lucentis® in patients with neovascular (wet) age-related macular degenerationCTRI/2018/05/014065Reliance Life Sciences Pvt Ltd159
已完成
3 期
A Comparative Clinical Study to Evaluate the effectiveness of DEXAMETHASONE-AGIO Injection in the treatment of severe or incapacitating allergic conditions of skin and respiratory tractCTRI/2017/10/010105Agio Pharmaceuticals Ltd60
已完成
3 期
A clinical trial to study the effects of two drugs, Dynapar QPS and placebo topical solution in patient suffering from osteoarthritis.Osteoarthritis of kneeCTRI/2015/02/005510Troikaa Pharmaceuticals Limited212